PATRYS
Patrys Limited develops natural human antibody-based therapeutic products for the treatment of lung, pancreatic, gastric, and colon cancers. The company's lead products include PAT-SM6 and PAT-LM1, which are anti-cancer natural human antibodies for the treatment of multiple cancers; and PAT-SC1 that completed Phase I/IIa trial for the treatment of gastric cancer. It also develops various human antibody discovery programs in infectious diseases for which treatments are needed, including programs ... in Hepatitis C, malaria, and Staphylococcus A. In addition, the company is exploring opportunities to use its technologies in other disease areas, such as cardiovascular, autoimmune, and central nervous system disorders. Patrys Limited has collaborations with AstraZeneca/Cambridge Antibody Technology and Debiopharm S.A. It operates in Australia, Germany, and the United States. The company was founded in 2006 and is headquartered in Melbourne, Australia.
PATRYS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2006-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.patrys.com
Total Employee:
11+
Status:
Active
Contact:
61 3 9670 3273
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Armaron Bio
Armaron Bio is a clinical stage biotechnology company.
Therapeutic Human Polyclonals
THP is an emerging biotechnology company focused on research in the field of human antibody technologies.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2008-10-27 | Acceptys | Acceptys acquired by Patrys | N/A |
Official Site Inspections
http://www.patrys.com
- Host name: cp-kil-swh-004.micron21.com
- IP address: 27.131.110.181
- Location: Kilsyth Australia
- Latitude: -37.8134
- Longitude: 145.3187
- Timezone: Australia/Melbourne
- Postal: 3137
More informations about "Patrys"
About - Patrys
In 2016, Patrys secured an exclusive, worldwide license from Yale University for the use of deoxymab antibodies as human therapeutic agents for treatment and management of cancer. …See details»
Patrys - Crunchbase Company Profile & Funding
Patrys Limited develops natural human antibody-based therapeutic products for the treatment of lung, pancreatic, gastric, and colon cancers. The company's lead products include PAT-SM6 …See details»
Investors – Patrys
For the astute biotechnology investor, Patrys offers a compelling opportunity. Our Deoxymab platform is a novel antibody exploiting its unique properties: the ability to target DNA processes inside the cell; the ability to cross the blood-rain …See details»
Patrys Limited - AnnualReports.com
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA …See details»
Patrys Limited (ASX: PAB) Company Profile & Overview - Stock …
Nov 7, 2024 Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops …See details»
Patrys Limited (ASX:PAB) - Intelligent Investor
5 days ago Patrys Limited (PAB), an ASX-listed company, is a publicly listed company based in Melbourne. The company is focused on the commercialisation of novel antibody therapeutics for oncology. Patrys' deoxymab platform is …See details»
Patrys Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Patrys Ltd. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 3 news, and 14 literature, Disease Domain:Neoplasms, Nervous System Diseases, Immune …See details»
Patrys - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Dec 10, 2024 Patrys is a clinical-stage biotechnology company focused on therapies for human cancers.See details»
Patrys Company Profile - Office Locations, Competitors, Revenue …
Patrys is a drug development company that commercializes antibody technologies for the treatment of cancer. It develops Deoxymab 3E10, a DNA damage-repair antibody that …See details»
Patrys - Products, Competitors, Financials, Employees, …
Patrys is a publicly-listed company engaged in the development of antibody technologies for oncology and NETosis-driven inflammatory diseases. The company's offerings include nuclear …See details»
Patrys Company Profile 2024: Stock Performance & Earnings
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 …See details»
ANNUAL REPORT 2022 - Patrys
At Patrys our research and development (R&D) is principally focused on treating some of the hardest cancers to access and treat. For example, a key development stream for Patrys is …See details»
Patrys - Overview, News & Similar companies | ZoomInfo.com
Nov 18, 2022 Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy MELBOURNE, Australia--(BUSINESS …See details»
Patrys - Contacts, Employees, Board Members, Advisors & Alumni
Patrys is a clinical-stage biotechnology company focused on therapies for human cancers.See details»
Patrys Ltd, PAB:ASX profile - FT.com - Financial Times
5 days ago Patrys Limited is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company’s …See details»
Patrys Annual Report 2020 extras
Patrys is innovating methodically and with great care, to uncover the full potential of its Deoxymab 3E10 platform. Patrys’ rights to Deoxymab 3E10 are part of a worldwide license to develop …See details»
Patrys Limited Director Updates Stock Options Holdings
1 day ago Patrys Limited has announced a change in the director’s interests, with James Campbell’s 11 million unlisted options expiring on December 18, 2024, now lapsed. Campbell …See details»
PAB News, Analysis, Announcements & Results | Patrys Limited | AFR
5 days ago Patrys is leveraging its proprietary deoxymab antibody technology platform to develop new therapies for the treatment of cancer and other diseases. PAB $ 0.004 0.00See details»
News – Patrys
Media Contact. Haley Chartres, H^CK Phone +61 423 139 163 Email [email protected]See details»
News - Patrys
Patrys’ Contract Development Manufacturing Organization (CDMO) has advised that its specification testing for the drug substance produced in the recent… ASX Announcements …See details»